Telbermin
Protein / enzyme therapeutic
Evidence outlook · program status
Discontinued (2015-10), after a negative readout
sNN0029 was Newron Sweden's intracerebroventricular VEGF-A infusion solution for amyotrophic lateral sclerosis. All continuation studies were terminated in October 2015 after an interim review found no favourable benefit-risk ratio, compounded by infusion-system supply problems. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02269436 NCT02269436 · Amyotrophic Lateral Sclerosis This trial continues patients from a completed earlier study rather than being a new stand-alone uncontrolled trial, but it is unblinded, single-arm, very small, and tracks safety only, so it offers limited evidence beyond that continuation context. Its registered primary outcome on ClinicalTrials.gov is "Number Patients with Adverse Events as a measure of Safety and Tolerability". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Registry: NCT02269436 | 1 | Number Patients with Adverse Events as a measure of Safety and Tolerability (At 24 Months) 2015-10 | Results not posted; external-source review pending | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
Other VEGF-A drugs
Aflibercept, aflibercept-abzv (Enzeevu), aflibercept-ayyh (Pavblu), aflibercept-boav (Eydenzelt), aflibercept-jbvf (Yesafili) and 33 more. Compare all 39 VEGF-A drugs
This mechanism is crowded: 38 other tracked programmes target it, 38 of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Telbermin: this drug | Discontinued | Protein / enzyme therapeutic | VEGF-A | Weak signal | No reviewed efficacy summary | |
| Aflibercept (Eylea) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF) | Reliable signal | NCT00509795: Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 95.1 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 95.9 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 95.1 percentage of patients (spread 0) vs Ranibizumab 0.5mg Q4 94.4 percentage of patients (spread 0) NCT00637377: Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (At week 52): Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 95.62% | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 96.27% | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 95.56% vs Ranibizumab 0.5mg Q4 94.42% | |
| Aflibercept-Abzv (Enzeevu) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary | |
| Aflibercept-Ayyh (Pavblu) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | Reliable signal | NCT04270747: Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): ABP 938 6.4 Letters (Standard Deviation 8.18) vs Aflibercept 6.5 Letters (Standard Deviation 8.97) | |
| Aflibercept-Boav (Eydenzelt) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary | |
| Aflibercept-Jbvf (Yesafili) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary | |
| Aflibercept-Mrbb (Ahzantive) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary | |
| Aflibercept-Yszy (Opuviz) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary | |
| Alymsys (bevacizumab-Maly) | Approved(overall) | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary | |
| BAT1706 (Avzivi) | Approved(overall) | Monoclonal antibody | VEGF-A | Partial signal | NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023). | |
| Bevacizumab | Approved(overall) | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | Partial signal | NCT00601900: Progression-free survival: hazard ratio 0.75 (95% CI 0.59 to 0.96; P=.016); median 20.2 months with letrozole plus bevacizumab vs 15.6 months with letrozole alone (CALGB 40503, J Clin Oncol 2016). NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo | |
| Bevacizumab-Awwb (MVASI) | Approved(overall) | Monoclonal antibody | VEGF-A | Reliable signal | NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results). | |
| Brolucizumab-Dbll | Approved(overall) | Antibody fragment | VEGF-A | Reliable signal | No reviewed efficacy summary | |
| Jobevne (bevacizumab-Nwgd) | Approved(overall) | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary | |
| Ranibizumab (Lucentis) | Approved(overall) | Antibody fragment | VEGF-A | Partial signal | NCT00056836: Losing fewer than 15 letters at 12 months: 94.5% (0.3 mg) and 94.6% (0.5 mg) vs 62.2% sham. | |
| Ranibizumab-Eqrn (Cimerli) | Approved(overall) | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary | |
| Ranibizumab-Hkdz (Ranluspec) | Approved(overall) | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary | |
| Ranibizumab-Leyk (Nufymco) | Approved(overall) | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary | |
| Ranibizumab-Nuna (Byooviz) | Approved(overall) | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary | |
| Vegzelma (bevacizumab-Adcd) | Approved(overall) | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary | |
| Zirabev (bevacizumab-Bvzr) | Approved(overall) | Monoclonal antibody | VEGF-A | Reliable signal | NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89) | |
| BAT5906 | Phase 3(overall) | Monoclonal antibody | VEGF-A | Partial signal | No reviewed efficacy summary | |
| CKD-701 (Lucenbies) | Phase 3(overall) | Monoclonal antibody | VEGF-A | Reliable signal | NCT04857177: Primary endpoint (proportion with <15-letter BCVA loss at 3 months): 97.95% (CKD-701) vs 98.62% (ranibizumab/Lucentis), P=0.67; between-group difference 0.66% (95% CI −3.63 to 2.32), within the pre-set equivalence margin (±11.5%). | |
| HD204 | Phase 3(overall) | Monoclonal antibody | VEGF-A | Reliable signal | NCT03390686: SAMSON-II (NCT03390686), primary endpoint ORR at week 18: HD204 48.7% vs reference bevacizumab 46.5%; risk ratio 1.047 (95% CI 0.86-1.27), within prespecified equivalence margin | |
| HLX04 (Hanbeitai) | Phase 3(overall) | Monoclonal antibody | VEGF-A | Partial signal | NCT03952403: ASTRUM-002 met the primary endpoint of progression-free survival with the combination of serplulimab plus HLX04 (bevacizumab biosimilar) and chemotherapy at interim analysis. A total of 636 patients were randomized 1:1:1 to serplulimab plus HLX04 and chemotherapy (group A), serplulimab plus HLX04 placebo and chemotherapy (group B), or double placebo plus chemotherapy (group C). Serplulimab plus chemotherapy significantly prolonged OS and maintained the PFS benefit compared to chemotherapy; however, the addition of the bevacizumab biosimilar HLX04 did not yield further improvement for first-line treatment of nonsquamous NSCLC. | |
| HLX04-O | Phase 3(overall) | Monoclonal antibody | VEGF-A | Partial signal | No reviewed efficacy summary | |
| IBI305 | Phase 3(overall) | Monoclonal antibody | VEGF-A | Reliable signal | NCT02954172: Objective response rate at 18 weeks: 44.3% IBI305 (n=221) vs 46.4% bevacizumab (n=220); odds ratio 0.90 (90% CI 0.756–1.077), prespecified equivalence margin 0.75–1.33. | |
| LY01008 | Phase 3(overall) | Monoclonal antibody | VEGF-A | Reliable signal | NCT03533127: LY01008 vs Avastin (bevacizumab) + paclitaxel/carboplatin, first-line non-squamous NSCLC: ORR 48.5% vs 53.0%; stratified ORR ratio 0.91 (90% CI 0.80-1.04), within prespecified equivalence margin 0.75-1.33 -> equivalence/non-inferiority demonstrated. | |
| Ranibizumab (Ximluci) | Phase 3(overall) | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary | |
| Surabgene Lomparvovec | Phase 3(overall) | Gene therapy / editing | VEGF-A | Weak signal | NCT04832724: Primary endpoint (aqueous RGX-314 protein at Month 6, high-dose cohorts): 511.7 ng/mL (BRX process, n=14) vs 436.3 ng/mL (HS process, n=14); 80% CI of the difference (-38, 189) overlaps 0 | |
| Tarcocimab Tedromer | Phase 3(overall) | Monoclonal antibody | VEGF-A | Reliable signal | NCT04964089: Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): KSI-301 (Treatment Group A) 2.5 ETDRS Letters (Standard Error 0.78) vs Aflibercept (Treatment Group B) 4.6 ETDRS Letters (Standard Error 0.76) NCT04592419: Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to Week 24 in BRVO Participants. (Day 1 to Week 24): KSI-301 (Arm A) 14.2 ETDRS Letters (Standard Error 0.81) vs Aflibercept (Arm B) 15.6 ETDRS Letters (Standard Error 0.79) | |
| MW02 | Phase 2/3(overall) | Monoclonal antibody | VEGF-A | Partial signal | No reviewed efficacy summary | |
| Ranibizumab (Rimmyrah) | Phase 1(overall) | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary | |
| Aflibercept (Afiveg) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary | |
| Aflibercept (Eyluxvi) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary | |
| Aflibercept (Mynzepli) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary | |
| Aflibercept (Vgenfli) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary | |
| Ranibizumab (Ranivisio) | —(overall) | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary | |
| Ranibizumab (Rexatilux) | —(overall) | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary |
Upcoming events
No upcoming readouts on record for this asset.